Theranexus and BBDF Win FDA Approval on Efficacy Endpoints f

Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions,The FDA confirmed that this sole Phase III trial would secure Batten-1

Related Keywords

United States , France , Paris , France General , French , Marie Sebille , Mathieu Charv , Craig Benson , Martin Pierre Laurent , Florence Portejoie , Thierry Lambert , Atomic Energy Commission , Twitter , Drug Administration , Batten Disease Foundation , Division Of Rare Diseases , National Organization For Rare Disorders , Beyond Batten Disease Foundation , Rare Diseases , Medical Genetics , Theranexu Chief Medical Officer Marie , Verbal Comprehension Index , Wechsler Intelligence Scale , Unified Batten Disease Rating Scale , French Alternative Energies , Euronext Growth , Rare Disorders , Gefallene Big Techs , Theranexus , Bbdf , Approval , Efficacy , Endpoints , Hase , Trial , Valuate , Thatten , Ln3 , Disease ,